Injectable Peptides in Sports Medicine: What Research Shows

As injectable peptides gain popularity among athletes and active patients seeking faster recovery and enhanced performance, a critical question remains: does the clinical evidence actually support their use? A structured narrative review published in JBJS Reviews in May 2026 offers one of the most comprehensive assessments to date — and its findings should give both clinicians and patients important pause before reaching for a syringe.

What This Study Found

Villegas Meza and colleagues conducted a systematic search of PubMed/MEDLINE, Embase, and Web of Science, covering human randomized controlled trials, prospective human studies, and translational investigations published between January 1, 2020, and August 31, 2025. Their focus was squarely on injectable peptide preparations relevant to musculoskeletal care and sports medicine. The researchers identified five functional classes of peptides currently being discussed or used in this context.

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, emerged as the only peptide class supported by reproducible randomized controlled trial evidence for musculoskeletal benefit. Specifically, the study found that GLP-1 receptor agonists demonstrated symptomatic improvement in knee osteoarthritis — but the researchers note this benefit appears to be primarily mediated by clinically meaningful weight loss and putative anti-inflammatory effects, rather than direct structural modification of cartilage. In other words, the joint may feel better largely because the patient weighs less, not because the peptide is repairing tissue.

Collagen-derived injectable preparations showed some preliminary postoperative symptom relief and early recovery benefits, but the evidence base consists only of small, single-center prospective human studies — a level of evidence insufficient to draw broad clinical conclusions.

Regenerative peptides — including Body Protection Compound-157 (BPC-157) and thymosin derivatives — and growth hormone axis secretagogues such as CJC-1295, ipamorelin, and tesamorelin remain investigational. The review found that these agents carry uncertain safety profiles, significant concerns about product quality, and are subject to widespread antidoping restrictions. The researchers did not identify high-quality human trial data supporting their routine clinical use for musculoskeletal indications.

The authors assigned their review a Level V evidence classification — the lowest tier — reflecting the current state of the literature and emphasizing that clinical adoption has substantially outpaced the available science.

Clinical Significance

The gap between how widely injectable peptides are being promoted and how limited the supporting evidence actually is represents a genuine patient safety concern. The study authors note explicitly that clinical use of injectable peptides should be confined to approved metabolic agents used for their indicated conditions — such as GLP-1 receptor agonists in patients with obesity-related knee osteoarthritis — and to rigorously designed research protocols.

For orthopaedic surgeons and sports medicine physicians, the review reinforces a cautious approach. Many of the peptides being marketed to athletes and recreational exercisers — BPC-157 and growth hormone secretagogues in particular — are not approved by the U.S. Food and Drug Administration (FDA) for clinical use, and compounded or gray-market versions raise additional concerns about purity, accurate dosing, and sterility. The study highlights that product quality concerns are a meaningful and underappreciated risk in this space.

It is also worth underscoring what the review found regarding regenerative peptides and secretagogues: the lack of high-quality human data does not mean these compounds are inert. Uncertain safety profiles cut both ways — we do not yet know the full scope of potential harms, particularly with long-term or repeated use in otherwise healthy athletes.

Current Access and Compliance Context

Athletes competing under the jurisdiction of the World Anti-Doping Agency (WADA) or the United States Anti-Doping Agency (USADA) face additional and immediate practical risks. The review specifically flags that growth hormone axis secretagogues and several regenerative peptides carry widespread antidoping restrictions. An athlete using a compounded or commercially sourced peptide that has not been rigorously tested for label accuracy could inadvertently consume a prohibited substance or trigger a positive test — regardless of intent.

Clinicians working with competitive athletes are urged by the study authors to provide clear counseling on this point. The intersection of unclear regulatory status, inconsistent product quality, and antidoping rules creates a compliance minefield that neither the athlete nor their healthcare provider should navigate casually.

For non-competitive patients, the regulatory landscape is only marginally simpler. Many injectable peptides available through wellness clinics or online compounding pharmacies operate in a legal gray area. Patients and providers alike should verify FDA approval status and ensure that any compounded product comes from a licensed, accredited pharmacy with verifiable quality controls.

What Patients Should Know

If you are an athlete, weekend warrior, or active patient who has seen injectable peptides promoted for injury recovery, joint health, or body composition, here is what the current evidence — as synthesized by this 2026 review — actually supports:

• GLP-1 receptor agonists (like semaglutide) have the strongest evidence for knee osteoarthritis symptom relief among peptides studied, but this benefit is linked primarily to weight reduction in eligible patients, not direct tissue repair. They are FDA-approved medications with established prescribing guidelines and require a legitimate clinical indication.
• BPC-157, thymosin derivatives, CJC-1295, ipamorelin, and similar compounds are considered investigational for musculoskeletal use. The study suggests their efficacy in humans has not been established through rigorous trials, and their safety in this context remains uncertain.
• Compounded peptide products carry inherent quality risks, including potential inaccuracies in concentration, sterility concerns, and the possibility of undisclosed ingredients.
• Competitive athletes should consult with a sports medicine physician familiar with current antidoping rules before using any injectable peptide, regardless of how it is marketed.
• A healthcare provider who recommends an injectable peptide should be able to explain the evidence base, the regulatory status of the product, and the known and unknown risks — and should be willing to document their clinical reasoning.

Being an informed patient in this space means asking hard questions. Enthusiasm in the marketplace is not a substitute for clinical evidence, and the authors of this review are clear: the science has not yet caught up with the hype.

Conclusion

The 2026 structured narrative review by Villegas Meza and colleagues provides a timely and rigorous snapshot of where injectable peptides actually stand in sports medicine and orthopaedics. The study suggests that only GLP-1 receptor agonists have meaningful randomized trial support for musculoskeletal indications, while the broader category of regenerative and performance-oriented peptides remains experimental, carries unresolved safety questions, and poses antidoping risks for competitive athletes. Responsible clinical use demands that evidence, regulatory status, and patient safety take precedence over marketing claims.

If you are considering injectable peptides for musculoskeletal recovery or sports performance, the most important first step is speaking with a qualified physician who specializes in this area. To find a knowledgeable provider near you, visit peptideassociation.org/find-a-doctor.

---

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified and licensed healthcare professional before starting, changing, or stopping any treatment or medication. The Peptide Association does not endorse any specific product, compound, or clinical protocol.

---

Citation: Villegas Meza AD, Nocek M, Mitchell BC, et al. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. JBJS Rev. 2026;14(5). doi:10.2106/JBJS.RVW.26.00027. PMID: 42160466.